Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:3.6.1.3 (ATPase)
 65,361 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Recently, we demonstrated that more beta-type myosin heavy chain (HC) was expressed in the overloaded atrium, and that there were 2 structurally different beta-type myosin heavy chains in the bovine heart. To determine the existence of the 2 beta-type HC in other animals and to clarify the characteristics of these beta-type HCs, we produced tricuspid regurgitation and pulmonary stenosis in the canine heart, and performed an immunological study using 3 monoclonal antibodies, 2 beta-type specific antibodies (HMC14 and 50) and 1 alpha-type specific antibody (CMA19). In an immunohistochemical study, serial cryostat sections revealed that some myofibers reacted with HMC50 (HC beta 2), but almost no fibers were labeled with HMC14 in the normal atrium. However, in overloaded atria, not only HC beta 2 but the HC, reacted with HMC14 (HC beta 1). By affinity chromatography, HC beta 2 was fractionated from normal atrial myosin using HMC50 and HC beta 1 was fractionated from overloaded atrial myosin using HMC14. These 2 HC beta's were subjected to digestion by alpha-chymotrypsin, staphylococcus aureus V8 protease, and cyanogen bromide, and proved to have different peptide fragments. In respect to enzymatic properties, the Ca2+-activated ATPase activities of HC beta 1 and beta 2 were almost the same but lower than that of HC alpha. We concluded that the isozymic transition of HC alpha to HC beta in the atrium was experimentally induced by hemodynamic overload and that HC beta 1, which was hardly recognized in the normal atrium but highly induced by overload, was structurally different from HC beta 2, as expressed in the normal atrium.
 ...
PMID:Isolation and characterization of two beta-type cardiac myosin in the canine atrium. 297 92

P-glycoprotein (P-gp) mediates a multidrug resistance (MDR) phenotype in tumor cell lines selected with lipophilic cytotoxic drugs. Transport studies using purified P-glycoprotein reconstituted into defined liposomes have shown energy-dependent drug efflux of structurally dissimilar drugs. In this report, we have examined the effects of N-ethylmaleimide, a potent inhibitor of the P-gp ATPase, on P-gp drug binding in intact MDR cells and in plasma membranes. Our results show that short term treatment of MDR cells with 1-50 microM N-ethylmaleimide led to a concentration dependent increase in P-gp photoaffinity labeling with iodoaryl-azidoparazosin (IAAP). In addition, N-ethylmaleimide increases [3H] vinblastine accumu-lation in drug-resistant but not in sensitive cells. Comparison of IAAP photolabeled P-gp from intact cells with or without N-ethylmaleimide treatment did not show differences in the pattern of IAAP photolabeled peptides. Thus, the observed increase in P-gp photolabeling with IAAP in N-ethylmaleimide treated cells is not due to photolabeling at different sites. Incubation of MDR cells with [14C] N-ethylmaleimide showed that P-gp is directly modified at several Cysteine residues, as found from a complete proteolytic digestion of [14C] Nethylmaleimide labeled P-gp. The comparison of V8 staphylococcus aureas peptides from [14C] Nethylmaleimide or IAAP modified P-gp showed some peptides to co-migrate on SDS PAGE. However, modification of plasma membranes from drug resistant cells treated with N-ethylmaleimide did not show a dose-dependent increase in P-gp photolabeling with IAAP as seen with intact MDR cells. Interestingly, N-ethylmaleimide increases P-gp phosphorylation by inhibiting the turnover of Pgp phosphates. However, inhibition of P-gp phosphorylation with calyculin A did not show an increase in P-gp photolabeling in MDR cells. Taken together, the results of this study suggest that N-ethylmaleimide potentiates P-gp photolabeling with IAAP by inhibiting P-gp ATPase thereby increasing the local concentration of IAAP in intact MDR cells. Furthermore, inhibition of P-gp ATPase by N-ethylmaleimide does not lead to conformational changes that affects P-gp drug binding.
 ...
PMID:N-ethylmaleimide increases P-glycoprotein photoaffinity labeling with iodoaryl-azidoprazosin in multidrug resistant cells. 906 77

It has been established that membrane vesicles of gonococci possess ATPase activity within 0.05-0.14 mmol of ATP during 60 min per 1 mg of protein and for staphylococcus--within 0.07-0.19 mmol of ATP for 60 min per 1 mg of protein. The identity in all the kinetic parameters is observed for all the studied gonococcus strains: Na+ and Ca2+ ions inhibit ATPase activity within 12-19%; Mg2+ ions increase the ATPase activity 2-2.5 times. Dicyclohexylcarboimide, a specific ATPase inhibitor, suppresses ATPase activity by 50-70%. ATPase activity in the strains of bacteria containing antibiotic-resistant plasmids is established to increase 1.2-2.8 times for gonococcus and 1.2-2.7 for staphylococcus as compared to sensitive ones.
 ...
PMID:[ATPase activity of Neisseria gonorrhoeae and Staphylococcus aureus strains]. 1178 16

The effect of staphylococcus active substances--protein A (PA) and peptidoglican (PG) at concentrations 10(-6)-10(-2) mg/ml on the ATPase activity of pig stomach natural actomyosin and myosin was studied. It was shown that PA and PG at direct contact with smooth muscle contractile proteins caused the activation and inhibition of ATPase activity, respectively. On the basis of this investigation it was assumed that staphylococcal active substances were able to modify of the ATPase activity smooth muscle contractile proteins perhaps via direct action on the myosin molecule, which could be accompanied by conformational changes of the active center of myosin ATPase.
 ...
PMID:[Effect of staphylococcus active substances on ATPase activity of smooth muscle actomyosin and myosin]. 1203 23